XARELTO®: Dosing in initial treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)

Once-daily treatment after 21 days of twice-daily dosing

15 mg

For the first 21 days, twice daily with food, at the same time each day in patients with CrCl ≥15 mL/min

20 mg

Starting at day 22, once daily with food, at the same time each day for remaining treatment in patients with CrCl ≥15 mL/min

15 mg

For the first 21 days, twice daily with food, at the same time each day in patients with CrCl ≥15 mL/min

20 mg

Starting at day 22, once daily with food, at the same time each day for remaining treatment in patients with CrCl ≥15 mL/min

Renal Dose Consideration*

  • Avoid using XARELTO® in patients with CrCl <15 mL/min

A convenient 30-day Starter Pack for patients with DVT/PE

Image of XARELTO® starter pack

For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.

*Calculate CrCl based on actual weight.

Patients with CrCl <30 mL/min were not studied, but administration of XARELTO® is expected to result in serum concentrations of rivaroxaban similar to those in patients with moderate renal impairment (CrCl 30 mL/min to <50 mL/min).

The decision regarding initiation setting should be based on the prescriber's clinical judgment.

CrCl = creatinine clearance; DVT = deep vein thrombosis; PE = pulmonary embolism; VTE = venous thromboembolism.